Pew Supports 37 Outstanding Early Career Researchers

Pew multimedia staff visit biomedical labs at The University of Pennsylvania, and the lab of 2012 Pew Biomedical Scholar Kathryn Wellen.© The Pew Charitable Trusts

The Pew Charitable Trusts announced today its 2015 class of biomedical scholars, Latin American fellows, and Pew-Stewart scholars for cancer research.

This class marks Pew’s 30th year supporting creative, curious scientists pursuing bold research in biomedical science. These 37 early-career researchers will receive funding to support their efforts and will join a community of more than 800 distinguished scientists dedicated to advancing human health.

Read the press releases announcing:

Biomedical Scholars Announcement Tile

National Homeownership Month

Article

37 Researchers Working to Transform Biomedical Science

Quick View
Article

Biomedical researchers are on the front lines of scientific innovation. From responding to global pandemics to pioneering lifesaving cancer treatments, these researchers push past scientific boundaries to solve pressing health challenges. For nearly 40 years, The Pew Charitable Trusts has supported more than 1,000 early-career biomedical scientists committed to this discovery.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.